CTT Pharmaceutical Holdings, Inc.

As of June 30, 2026, CTT Pharmaceutical Holdings, Inc. carries a market capitalization of 4.48M, placing it among publicly traded companies globally. Its enterprise value stands at 4.50M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, CTT Pharmaceutical Holdings, Inc. has 59.72M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, CTT Pharmaceutical Holdings, Inc. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 74.65, indicating elevated leverage, while an interest coverage ratio of -248.78 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, CTT Pharmaceutical Holdings, Inc. posted a negative return on equity (ROE) of -306.04, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -195.21, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 1.25, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, CTT Pharmaceutical Holdings, Inc.'s stock has declined approximately 15.32% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.07.

Over the twelve months ended June 30, 2026, CTT Pharmaceutical Holdings, Inc. generated - - in revenue and converted that into -165,542.00 in net income, yielding earnings per share of 0.00. EBITDA reached -156,235.00, while operating income came in at -162,873.00.

As of June 30, 2026, CTT Pharmaceutical Holdings, Inc. holds 31.00 in cash and equivalents against 19,442.00 in total debt, resulting in a net debt position of 19,411.00. Total book value stands at 26,043.00, with working capital of -41,360.00 providing operational flexibility.

CTT Pharmaceutical Holdings, Inc. produced -53,813.00 in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3,952.00 in capital expenditures, free cash flow totaled -57,765.00 - equivalent to 0.00 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.31: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.57, meaning CTT Pharmaceutical Holdings, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

CTT Pharmaceutical Holdings, Inc.'s most recent stock split took place on August 28, 2015 with a 10:1 split ratio.

As of June 30, 2026, CTT Pharmaceutical Holdings, Inc. has an Altman Z-Score of -364,419.98, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.